Request Demo
Last update 28 Jan 2026
iNeo-Vac-R01
Last update 28 Jan 2026
Overview
Basic Info
Drug Type Therapeutic vaccine, mRNA vaccine |
Synonyms iNeo-Vac-R01 |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with iNeo-Vac-R01NCT06956716
Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen mRNA Therapy in Combination With PD-1 Antibody and Chemotherapy for Advanced Intrahepatic Cholangiocarcinoma
NCT06995105
Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen mRNA Therapy Combined With PD-1 Monoclonal Antibody and TACE for Advanced Hepatocellular Carcinoma
NCT06888674
Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen MRNA Therapy Combined with PD-1 Antibody and Chemotherapy As Adjuvant Treatment for Postoperative Pancreatic Cancer.
100 Clinical Results associated with iNeo-Vac-R01
Login to view more data
100 Translational Medicine associated with iNeo-Vac-R01
Login to view more data
100 Patents (Medical) associated with iNeo-Vac-R01
Login to view more data
100 Deals associated with iNeo-Vac-R01
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Liver metastases | Phase 2 | China | 11 Sep 2025 | |
| Advanced Hepatocellular Carcinoma | Phase 2 | China | 09 Apr 2025 | |
| Intrahepatic Cholangiocarcinoma | Phase 2 | China | 09 Apr 2025 | |
| Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | China | 09 Apr 2025 | |
| Metastatic Pancreatic Cancer | Phase 2 | China | 01 Apr 2025 | |
| Pancreatic Cancer | Phase 2 | China | 01 Apr 2025 | |
| Pancreatic carcinoma non-resectable | Phase 2 | China | 01 Apr 2025 | |
| Pancreatic Ductal Adenocarcinoma | Phase 2 | China | 01 Apr 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free